Cargando…

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

BACKGROUND: Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density lipoprotein cholesterol (non-HDL-C), cholesterol transported by apolipoprotein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzatti, Alberto J., Monsalvo, Maria Laura, López, J. Antonio G., Wang, Huei, Rosenson, Robert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091704/ https://www.ncbi.nlm.nih.gov/pubmed/33941192 http://dx.doi.org/10.1186/s12933-021-01287-6

Ejemplares similares

Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial
por: Lorenzatti, Alberto J., et al.
Publicado: (2019)

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
por: Rosenson, Robert S., et al.
Publicado: (2019)

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial
por: Chen, Yundai, et al.
Publicado: (2019)

Atherogenic dyslipidemia
por: Manjunath, C. N., et al.
Publicado: (2013)

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Lorenzatti, Alberto J, et al.
Publicado: (2020)

Banting in India, with Remarks on Diet
Publicado: (1885)

Plasma vitamin D and parathormone are associated with obesity and atherogenic dyslipidemia: a cross-sectional study
por: Guasch, Alba, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
por: Alghamdi, Ahmed, et al.
Publicado: (2021)

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
por: Tan, Hong, et al.
Publicado: (2023)

Frederick Banting's observations leading to the potential for islet neogenesis without transplantation
por: Levetan, Claresa
Publicado: (2021)

How to Get Thin; or Banting in India
Publicado: (1878)

Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study
por: Valensi, Paul, et al.
Publicado: (2016)

Banting Lecture 2011: Hyperinsulinemia: Cause or Consequence?
por: Corkey, Barbara E.
Publicado: (2012)

Search for genetic factors predisposing to atherogenic dyslipidemia
por: Yip, Agustin G, et al.
Publicado: (2003)

Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention
por: Musunuru, Kiran
Publicado: (2010)

Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
por: Vekic, Jelena, et al.
Publicado: (2023)

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?
por: Kumar, Ajoy, et al.
Publicado: (2010)

The Association of Dyslipidemia and Atherogenic Indices With Glycemic Control in Diabetic Dyslipidemia Patients: A Real-World Landscape
por: Bage, Isaac J, et al.
Publicado: (2023)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
por: Toth, Peter P., et al.
Publicado: (2020)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
por: Koren, Michael J., et al.
Publicado: (2020)

Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies
por: Daviglus, Martha L., et al.
Publicado: (2020)

Adipocyte Triglyceride Turnover Is Independently Associated With Atherogenic Dyslipidemia
por: Frayn, Keith, et al.
Publicado: (2012)

Atherogenic Dyslipidemia and Cardiovascular Risk Factors in Obese Children
por: D'Adamo, Ebe, et al.
Publicado: (2015)

Hibernating brown bears are protected against atherogenic dyslipidemia
por: Giroud, Sylvain, et al.
Publicado: (2021)

Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
por: Munigoti, Srinivasa P., et al.
Publicado: (2014)

Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects
por: Montali, Anna, et al.
Publicado: (2015)

Atherogenic Dyslipidemia and Residual Vascular Risk in Practice of Family Doctor
por: Alibasic, Esad, et al.
Publicado: (2015)

Glycative Stress, Glycated Hemoglobin, and Atherogenic Dyslipidemia in Patients with Hyperlipidemia
por: Yao, Chien-An, et al.
Publicado: (2023)

Prevalence of dyslipidemia, atherogenic and cardiovascular risk in overweight and obese adolescents
por: de Andrades, Clara dos Santos, et al.
Publicado: (2023)

Banting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes
por: Taylor, R
Publicado: (2013)

Independent association of atherogenic dyslipidaemia with all‐cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study
por: Orsi, Emanuela, et al.
Publicado: (2021)

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes
por: Blom, Dirk J., et al.
Publicado: (2020)

The Multifaceted Roles of Adipose Tissue—Therapeutic Targets for Diabetes and Beyond: The 2015 Banting Lecture
por: Scherer, Philipp E.
Publicado: (2016)

Following in Banting’s footsteps or straying from the path? Observations from contemporary diabetes innovation
por: Leadley, Connor, et al.
Publicado: (2023)

High Density Lipoprotein Particle Size in Children: Relation to Atherogenic Dyslipidemia
por: Numata, Michio
Publicado: (2004)

Correction: Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects
por: Montali, Anna, et al.
Publicado: (2015)

Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
por: Akhtar, Daud H., et al.
Publicado: (2019)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_banduo9bqjeiea1otngqlvbuor